Combipenix which contains 125 mg (potency) of ABPC and 62. 5 mg (potency) of MDIPC per capsule was administered orally in a dose of 3 capsules q. i. d. for 2 weeks to complicated urinary tract infections, and clinical and fundamental studies on this drug were made with the results summarized as follows :
1. Excellent clinical results were obtained in 7 cases out of 30 (23 3%).
2. Combipenix, confirmed by MICs, has shown its synergistic effect against 5, namely 2 strains of E. coli and 3 of Pseudomonas, out of 24 strains of gram-negative bacteria.
3. In the case of patients with impaired renal function, urinary excretion of MDIPC was observed to be low.
4. In vitro experiments using residual urine from the patients with urinary tract infections showed only slight synergistic effect of Combipenix, and the inactivation of ABPC was remarkable.
5. No side effect due to Combipenix was observed.